As a pioneer in muscle biology and the mechanics of muscle, we have developed a broad and diverse pipeline of cardiovascular and neuromuscular muscle-directed medicines with the potential to improve muscle function in diseases of impaired contractility.
At Cytokinetics we are committed to rigorous research to elaborate on the safety and efficacy of our potential medicines. Over our 25-year history, we have conducted more than 100 clinical trials in partnership with hundreds of research institutions across the world, and are grateful to the tens of thousands of patients who have contributed to our development programs.
Evaluating the efficacy and safety of CK-586 in subgroup of patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with hypercontractility and ventricular hypertrophy.
Evaluating the efficacy and safety of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF).
Evaluating the efficacy and safety of aficamten in a broad and expansive clinical trial program spanning obstructive and non-obstructive hypertrophic cardiomyopathy.
Conducted some of the largest clinical trials in ALS, culminating in the Phase 3 clinical trial, COURAGE-ALS.